CG ONCOLOGY INC (CGON) Fundamental Analysis & Valuation

NASDAQ:CGON • US1569441009

Current stock price

67.48 USD
+0.69 (+1.03%)
At close:
67.48 USD
0 (0%)
After Hours:

This CGON fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CGON Profitability Analysis

1.1 Basic Checks

  • In the past year CGON has reported negative net income.
  • CGON had a negative operating cash flow in the past year.
  • In the past 5 years CGON always reported negative net income.
  • In the past 5 years CGON always reported negative operating cash flow.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • CGON has a Return On Assets of -20.34%. This is in the better half of the industry: CGON outperforms 76.60% of its industry peers.
  • With an excellent Return On Equity value of -21.39%, CGON belongs to the best of the industry, outperforming 81.04% of the companies in the same industry.
Industry RankSector Rank
ROA -20.34%
ROE -21.39%
ROIC N/A
ROA(3y)-22.01%
ROA(5y)-25.4%
ROE(3y)-23.36%
ROE(5y)-30.15%
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -10 -20 -30 -40

1.3 Margins

  • CGON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CGON Health Analysis

2.1 Basic Checks

  • CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CGON has more shares outstanding
  • CGON has a worse debt/assets ratio than last year.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 20M 40M 60M 80M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 87.33 indicates that CGON is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 87.33, CGON belongs to the best of the industry, outperforming 98.07% of the companies in the same industry.
  • CGON has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • CGON has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 87.33
ROIC/WACCN/A
WACC9.24%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 24.63 indicates that CGON has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 24.63, CGON belongs to the top of the industry, outperforming 97.10% of the companies in the same industry.
  • CGON has a Quick Ratio of 24.58. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 24.58, CGON belongs to the best of the industry, outperforming 97.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.63
Quick Ratio 24.58
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CGON Growth Analysis

3.1 Past

  • CGON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -47.18%.
  • Looking at the last year, CGON shows a very strong growth in Revenue. The Revenue has grown by 254.70%.
  • CGON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 176.56% yearly.
EPS 1Y (TTM)-47.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.42%
Revenue 1Y (TTM)254.7%
Revenue growth 3Y176.56%
Revenue growth 5YN/A
Sales Q2Q%409.21%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.63% on average over the next years. This is a very strong growth
  • CGON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 279.64% yearly.
EPS Next Y-20.3%
EPS Next 2Y-0.51%
EPS Next 3Y26.84%
EPS Next 5Y36.63%
Revenue Next Year1006.85%
Revenue Next 2Y754.74%
Revenue Next 3Y535.28%
Revenue Next 5Y279.64%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. CGON Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CGON. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CGON's earnings are expected to grow with 26.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.51%
EPS Next 3Y26.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CGON Dividend Analysis

5.1 Amount

  • No dividends for CGON!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CGON Fundamentals: All Metrics, Ratios and Statistics

CG ONCOLOGY INC

NASDAQ:CGON (4/2/2026, 8:13:47 PM)

After market: 67.48 0 (0%)

67.48

+0.69 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27
Earnings (Next)05-11
Inst Owners110.65%
Inst Owner Change4.64%
Ins Owners0.04%
Ins Owner Change3.03%
Market Cap5.70B
Revenue(TTM)4.04M
Net Income(TTM)-161.00M
Analysts83.81
Price Target84.03 (24.53%)
Short Float %13.6%
Short Ratio8.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.82%
Min EPS beat(2)0.21%
Max EPS beat(2)15.43%
EPS beat(4)2
Avg EPS beat(4)-2.26%
Min EPS beat(4)-15.32%
Max EPS beat(4)15.43%
EPS beat(8)4
Avg EPS beat(8)-2.23%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1390.27%
Min Revenue beat(2)379.26%
Max Revenue beat(2)2401.28%
Revenue beat(4)2
Avg Revenue beat(4)651.12%
Min Revenue beat(4)-100%
Max Revenue beat(4)2401.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.93%
PT rev (3m)14.27%
EPS NQ rev (1m)12.54%
EPS NQ rev (3m)13.42%
EPS NY rev (1m)5.56%
EPS NY rev (3m)5.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-40.96%
Revenue NY rev (3m)-40.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1410.4
P/FCF N/A
P/OCF N/A
P/B 7.57
P/tB 7.68
EV/EBITDA N/A
EPS(TTM)-2.09
EYN/A
EPS(NY)-2.51
Fwd EYN/A
FCF(TTM)-1.57
FCFYN/A
OCF(TTM)-1.57
OCFYN/A
SpS0.05
BVpS8.91
TBVpS8.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.34%
ROE -21.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.01%
ROA(5y)-25.4%
ROE(3y)-23.36%
ROE(5y)-30.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.27%
Cap/Sales 3.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.63
Quick Ratio 24.58
Altman-Z 87.33
F-Score3
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.42%
EPS Next Y-20.3%
EPS Next 2Y-0.51%
EPS Next 3Y26.84%
EPS Next 5Y36.63%
Revenue 1Y (TTM)254.7%
Revenue growth 3Y176.56%
Revenue growth 5YN/A
Sales Q2Q%409.21%
Revenue Next Year1006.85%
Revenue Next 2Y754.74%
Revenue Next 3Y535.28%
Revenue Next 5Y279.64%
EBIT growth 1Y-66.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.92%
EBIT Next 3Y3.21%
EBIT Next 5YN/A
FCF growth 1Y-67.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.14%
OCF growth 3YN/A
OCF growth 5YN/A

CG ONCOLOGY INC / CGON Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CG ONCOLOGY INC?

ChartMill assigns a fundamental rating of 3 / 10 to CGON.


Can you provide the valuation status for CG ONCOLOGY INC?

ChartMill assigns a valuation rating of 1 / 10 to CG ONCOLOGY INC (CGON). This can be considered as Overvalued.


How profitable is CG ONCOLOGY INC (CGON) stock?

CG ONCOLOGY INC (CGON) has a profitability rating of 1 / 10.


What is the financial health of CG ONCOLOGY INC (CGON) stock?

The financial health rating of CG ONCOLOGY INC (CGON) is 5 / 10.


What is the expected EPS growth for CG ONCOLOGY INC (CGON) stock?

The Earnings per Share (EPS) of CG ONCOLOGY INC (CGON) is expected to decline by -20.3% in the next year.